Aetna color-flow Doppler echocardiography Coverage | OpenPayer

Loading...

Aetna color-flow Doppler echocardiography Coverage | OpenPayer

inv-01: Medically necessary indications — Covered when ANY of the following indications are present

Covered when ANY of the following indications are present

During excision of left atrial mass.

From policy medical necessity list.

Evaluation of angina.

From policy medical necessity list.

Evaluation of aortic diseases.

From policy medical necessity list.

Evaluation of aortocoronary bypass grafts.

From policy medical necessity list.

Evaluation of atrial fibrillation/flutter.

From policy medical necessity list.

Evaluation of cardiac function after the Fontan procedure.

From policy medical necessity list.

Evaluation of cardiac tamponade.

From policy medical necessity list.

Evaluation of cardiomyopathy (including hypertrophic cardiomyopathy).

From policy medical necessity list.

Evaluation of congestive heart failure.

From policy medical necessity list.

Evaluation of dyspnea (shortness of breath).

From policy medical necessity list.

Evaluation of heart murmur.

From policy medical necessity list.

Evaluation of pericardial effusion.

From policy medical necessity list.

Evaluation of prosthetic valves.

From policy medical necessity list.

Evaluation of pulmonary hypertension.

From policy medical necessity list.

Evaluation of septal defects.

From policy medical necessity list.

Evaluation of site of intracardiac shunts: Evaluation of site of left-to-right or right-to-left shunts.

From policy medical necessity list.

Evaluation of valvular diseases (including mitral regurgitation and assessment of valve stenosis severity).

From policy medical necessity list.

Monitoring after repair of tetralogy of Fallot: Monitoring of individuals after repair of tetralogy of Fallot.

From policy medical necessity list.

Monitoring of individuals receiving cardiotoxic chemotherapy.

From policy medical necessity list.

Status post an episode of ventricular tachycardia.

From policy medical necessity list.

inv-02: Clinical Indications / Monitoring Contexts — Indications and clinical roles described in the document include the following contexts

Indications and clinical roles described in the document include the following contexts

Surveillance after tetralogy of Fallot repair: Echocardiography is recommended annually until age 10 and every 2 years through adulthood to detect residual septal defects; assess severity of pulmonary insufficiency; identify persistent RVOT obstruction (site and severity); and assess RV and LV size, function, wall motion, and aortic root/valve status.

UpToDate guidance summarized in policy.

Monitoring during/after cardiotoxic chemotherapy: Transthoracic echocardiography is the primary modality for detection of cancer therapeutics–related cardiac dysfunction; myocardial deformation imaging (GLS by speckle tracking or tissue Doppler strain) can detect early changes before LVEF decline; a 10%–15% early reduction in GLS is predictive of cardiotoxicity.10-15% GLS reduction

Systematic reviews and guideline summaries cited (Thavendiranathan et al, McGregor et al).

Evaluation after ventricular tachycardia:

Color-flow Doppler echocardiography is considered experimental and investigational for indications other than those explicitly listed as medically necessary in this policy (for example, to guide catheter ablation in ventricular tachycardia).

There is insufficient evidence to support the use of color-flow Doppler echocardiography during ventricular tachycardia ablation; the UpToDate review cites a single small series (Ren et al., n=4), and published data are limited to small case reports/series.

The referenced policy text and appendix do not list any additional explicit exclusions beyond the experimental/investigational statement; documentation guidance focuses on billing the diagnostic test findings as the primary indication.

Consistent with the experimental/investigational designation, use of color-flow Doppler echocardiography to guide ventricular tachycardia ablation is not supported by the available evidence and is therefore considered investigational for that application.

Within the cited policy chunks there are no explicit statements using the phrase "not medically necessary"; the document instead uses the terms medically necessary for listed indications and experimental and investigational for other uses.

Coding — CPT, HCPCS and ICD-10 References

Prior Authorization

Prior Authorization / Coverage Highlight

Prior Authorization Required: CPT 93325 is a covered add-on code when selection criteria are met; ensure prior authorization is obtained when applicable.

CPT 93325: Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)

Note

Echocardiography for Pericardial Disease

Provider action: Echocardiography is indicated for evaluation of pericardial disease (eg, pericardial effusion, cardiac tamponade) and should be documented with the appropriate ICD-10 diagnosis code (for example I31.31, I31.39 for pericardial effusion; I31.4 for cardiac tamponade).

I31.31, I31.39: Pericardial effusion (noninflammatory)
I31.4: Cardiac tamponade

Denial Risk

Denial Risk for Unestablished Indications

Denial Risk: Studies or uses not supported by established indications (including experimental guidance of ventricular tachycardia catheter ablation procedures and certain intracardiac/device ablation adjuncts) may be denied. Document the clinical indication, rationale, and supporting diagnostic findings.

Codes/procedures flagged as experimental/investigational in this policy include: 93650, 93653, 93654, and HCPCS C1886.
Claims for echocardiography to guide catheter ablation of ventricular tachycardia should include supporting documentation demonstrating established clinical utility.

Documentation Required

Coding Documentation Requirements

Billing and Coding Documentation: Include the reason for the study, pertinent clinical findings, and the specific echocardiographic components performed. When reporting add-on codes (eg, 93325, 93320, 93321), document the primary echocardiography service and the medical necessity for the additional Doppler/color-flow mapping or spectral Doppler.

List the primary echocardiography CPT (eg, 93306, 93308, 93350) and append add-on codes as appropriate (eg, +93325, +93320, +93321).
For perinatal/fetal studies, use the appropriate fetal CPTs (eg, 76825-76828) and ICD-10 codes indicating fetal cardiac concern.
Ensure ICD-10 diagnosis codes supporting medical necessity are present on the claim (see Covered ICD-10 Codes group).

Covered CPT/HCPCS CodesCPTCovered

93325	Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)
93306	Echocardiography, transthoracic, real-time with image documentation (2D), complete, with spectral Doppler and color flow
93308	Echocardiography, transthoracic, follow-up or limited study
93350	Echocardiography, transthoracic, during stress test, with interpretation and report
93351	As 93350 including continuous ECG monitoring with physician supervision
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or repeat study
93312	Transesophageal echocardiography, real time with 2D image documentation
93314	Transesophageal echocardiography, image acquisition, interpretation and report only
93315	Transesophageal echocardiography for congenital cardiac anomalies; with probe placement, interpretation and report

Related / Parent CPT and HCPCS CodesCPT

75561	Cardiac MRI for morphology and function without and with contrast
76825	Fetal echocardiography, 2D with or without M-mode
76826	Fetal echocardiography follow-up or repeat study
76827	Fetal Doppler echocardiography, complete
76828	Fetal Doppler echocardiography, follow-up or repeat study
93650	Intracardiac catheter ablation of AV node function (policy lists as experimental/investigational to guide VT ablation)
93653	Comprehensive electrophysiologic evaluation (experimental/investigational to guide VT ablation)
93654	Comprehensive EP evaluation with VT ablation (experimental/investigational to guide VT ablation)

Covered ICD-10 CodesICD-10Covered

A40.0 - A40.9	Streptococcal sepsis
A41.01 - A41.02	Sepsis due to Staphylococcus aureus
A41.50	Gram-negative sepsis, unspecified
A52.03	Syphilitic endocarditis
B39.4	Histoplasmosis capsulati (pericarditis) — must be billed with I32 or I39 as applicable
C38.0	Malignant neoplasm of heart
I01.1 - I01.9	Acute rheumatic endocarditis/myocarditis and related
I20.0 - I20.9	Angina pectoris
I21.01 - I22.9	Acute myocardial infarction
I31.31, I31.39	Pericardial effusion (noninflammatory)

1–10 of 18

1/2

Provider Actions, Billing and Documentation

Note

Echocardiography as initial imaging for pericardial disease

Two‑dimensional and Doppler echocardiography are recommended as the initial imaging technique to assess the hemodynamic impact of pericardial effusion and to guide timing of pericardiocentesis.

Use echocardiography to assess hemodynamic significance and to help decide timing of pericardiocentesis.
Repeat echocardiography during follow-up if suspicion for tamponade remains or effusion is large/rapidly accumulating.

Note

Prior authorization — policy history

Policy history documents review and effective dates, but these policy‑history entries do not list separate prior authorization codes or explicit PA requirements.

Last review: 03/14/2023; Effective date: 07/31/1995; Next review: 01/11/2024.

Note

Step Therapy

ECP initial therapy — start with anti‑inflammatory agents

For effusive‑constrictive pericarditis (ECP), anti‑inflammatory agents are first‑line therapy; pericardiectomy is reserved for cases refractory to medical therapy.

Diagnose ECP using clinical and echocardiographic features; initiate anti‑inflammatory treatment first.
Consider pericardiectomy only if ECP is refractory to medical management.

Note

Billing Rule

Coding — bill covered codes when selection criteria met

Bill CPT/HCPCS and ICD‑10 codes consistent with the codes enumerated in the policy when the selection criteria are met; the policy lists 93325 and numerous related echocardiography procedure codes.

Ensure coding matches the specific procedure performed (e.g., 93306 for complete TTE with color flow; 93325 as an add‑on for color‑flow velocity mapping).

Documentation Required

Fontan follow‑up — include deformation and quantitative indices

When advanced quantitative assessment after the Fontan procedure is performed, include deformation measures and other quantitative indices in the clinical report; acquisition and measurement times were documented in the referenced series.

Report deformation measures (strain) and other quantitative indices in the clinical report.
Document acquisition and measurement times as part of the study record.

Documentation Required

Documentation and billing — bill findings as primary indication

Per Medicare Diagnostic Imaging Billing guidance, bill the findings of the diagnostic test as the primary indication rather than the referring physician’s diagnosis; follow ICD coding guidance for diagnostic imaging.

List the diagnostic finding as the principal indication on claims per the Medicare Claims Processing Manual, Chapter 13.

Denial Risk

Denial risk — unestablished indications may be denied

Use of color‑flow Doppler echocardiography for indications other than those listed as medically necessary (for example, to guide catheter ablation in ventricular tachycardia) may be considered experimental/investigational and is subject to denial.

Avoid billing for color‑flow Doppler echocardiography for unlisted indications without prior authorization or strong supporting documentation.

Note

Pericardial effusion/tamponade — perform echocardiographic evaluation

Echocardiography is recommended as the initial imaging test for suspected pericardial effusion/tamponade and should be used to guide timing of pericardiocentesis; failure to perform appropriate echocardiographic assessment when indicated may lead to inadequate care decisions.

Perform 2D and Doppler echocardiography to assess hemodynamic significance in suspected tamponade.
Repeat imaging if clinical suspicion persists or effusion is large/rapidly accumulating.

Billing Rule

Billing note — list imaging findings as primary indication

Per Medicare guidance, physicians should bill the diagnostic test findings as the primary indication rather than the referring physician’s diagnosis to align with diagnostic imaging billing rules.

Ensure claim diagnosis coding reflects the imaging finding as the principal indication per Medicare Claims Processing Manual, Chapter 13.

Definitions and Key Terms

Color Doppler echocardiography (color flow Doppler)

DefinitionColor Doppler echocardiography (color flow Doppler) is 2-D Doppler echocardiography with flow encoded in color to show direction (red toward, blue away) and velocity displayed as color-coded pixels

Primary usesAssessing valve regurgitation and stenosis, detecting intracardiac shunts, and imaging blood flow in the heart

Technique noteColor flow mapping measures velocity along each sector line of a 2-D image and displays it as color-coded pixels

Echocardiography modalities

Two-dimensional (2-D) echocardiographyProvides spatially correct real-time tomographic images of the heart for assessment of chamber size, wall thickness, global/regional systolic function, and valvular/vascular structures

M-mode echocardiographyCreates a continuous 1-D graphic display useful for measuring single dimensions of walls and chambers to estimate volumes and LV mass

Spectral DopplerRecords velocity, direction, and type of blood flow displayed on a strip chart (pulsed and/or continuous wave) for quantitative flow assessment

Color flow imaging typical uses

Typical screening usesScreening and assessment of regurgitant flows (valvular regurgitation)

Shunt assessmentDetection and evaluation of intracardiac shunts such as atrial and ventricular septal defects

Other usesAssessment of pulmonary vein flow and assisting continuous-wave Doppler alignment for tricuspid regurgitation velocities

Effusive-constrictive pericarditis (ECP)

DefinitionEffusive-constrictive pericarditis (ECP) is the coexistence of a hemodynamically significant pericardial effusion and decreased pericardial compliance

Key clinical featureHallmark is persistence of elevated right atrial pressure after pericardiocentesis

Management summaryAnti-inflammatory agents are first-line; pericardiectomy reserved for refractory cases

Monitoring after Tetralogy of Fallot repair (surveillance frequency)

Surveillance frequency (pediatric origin)Echocardiography recommended annually until age 10 and every 2 years thereafter into adulthood after tetralogy of Fallot repair

Monitoring focusDetect residual septal defects, assess pulmonary insufficiency, RVOT obstruction, RV/LV size and function, and aortic root/valve status

Context noteGuidance derived from UpToDate review on management and outcomes of tetralogy of Fallot

GLS (global longitudinal strain): definition and threshold

DefinitionGlobal longitudinal strain (GLS) by speckle-tracking echocardiography is a myocardial deformation parameter measuring longitudinal shortening

Clinical significanceGLS detects early myocardial dysfunction that precedes reductions in left ventricular ejection fraction and predicts cardiotoxicity

Actionable thresholdA 10% to 15% early relative reduction in GLS during therapy is predictive of chemotherapy-related cardiotoxicity